Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Parikh

Showing results (271-280 of 385) with videos related to

Pageof 39
Sort By:
Brain and Behavior|March 25, 2022
Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapyCaroline W Espinola, Yuelee Khoo, Roohie Parmar, et al.
Focus (American Psychiatric Publishing)|February 5, 2020
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine TreatmentsArun V Ravindran, Lynda G Balneaves, Guy Faulkner, et al.
Arthritis Care & Research|August 30, 2022
Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus NephritisCristina Arriens, Y K Onno Teng, Ellen M Ginzler, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|August 4, 2016
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine TreatmentsArun V Ravindran, Lynda G Balneaves, Guy Faulkner, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 6, 2020
Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus NephritisJuan M Mejia-Vilet, John P Shapiro, Xiaolan L Zhang, et al.
CNS Drugs|April 16, 2021
Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study ReportEmma Morton, Venkat Bhat, Peter Giacobbe, et al.
Circulation. Cardiovascular Quality and Outcomes|September 3, 2020
Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American PopulationsRishi V Parikh, Danielle M Nash, K Scott Brimble, et al.
Lancet (London, England)|May 10, 2021
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialBrad H Rovin, Y K Onno Teng, Ellen M Ginzler, et al.
Psychological Medicine|May 16, 2022
Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysisMehri Sajjadian, Raymond W Lam, Roumen Milev, et al.
JAMA Network Open|September 28, 2023
Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant MedicationBenjamin Schwartzmann, Prabhjot Dhami, Rudolf Uher, et al.
Pageof 39

Showing results (271-280 of 385) with videos related to

Sort By:
Pageof 39
Brain and Behavior|March 25, 2022
Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapyCaroline W Espinola, Yuelee Khoo, Roohie Parmar, et al.
Focus (American Psychiatric Publishing)|February 5, 2020
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine TreatmentsArun V Ravindran, Lynda G Balneaves, Guy Faulkner, et al.
Arthritis Care & Research|August 30, 2022
Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus NephritisCristina Arriens, Y K Onno Teng, Ellen M Ginzler, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|August 4, 2016
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine TreatmentsArun V Ravindran, Lynda G Balneaves, Guy Faulkner, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 6, 2020
Association Between Urinary Epidermal Growth Factor and Renal Prognosis in Lupus NephritisJuan M Mejia-Vilet, John P Shapiro, Xiaolan L Zhang, et al.
CNS Drugs|April 16, 2021
Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study ReportEmma Morton, Venkat Bhat, Peter Giacobbe, et al.
Circulation. Cardiovascular Quality and Outcomes|September 3, 2020
Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American PopulationsRishi V Parikh, Danielle M Nash, K Scott Brimble, et al.
Lancet (London, England)|May 10, 2021
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialBrad H Rovin, Y K Onno Teng, Ellen M Ginzler, et al.
Psychological Medicine|May 16, 2022
Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysisMehri Sajjadian, Raymond W Lam, Roumen Milev, et al.
JAMA Network Open|September 28, 2023
Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant MedicationBenjamin Schwartzmann, Prabhjot Dhami, Rudolf Uher, et al.
Pageof 39